Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Gillian Worthy"'
Autor:
Peter P. Toth, Gillian Worthy, Shravanthi R. Gandra, Naveed Sattar, Sarah Bray, Lung‐I. Cheng, Ian Bridges, Gavin M. Worth, Ricardo Dent, Carol A. Forbes, Sohan Deshpande, Janine Ross, Jos Kleijnen, Erik S. G. Stroes
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 10 (2017)
BackgroundThe proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reducti
Externí odkaz:
https://doaj.org/article/7f9fd7632f2a455c94947fb72b3ea045
Autor:
Sally Brabyn, Ricardo Araya, Michael Barkham, Peter Bower, Cindy Cooper, Ana Duarte, David Kessler, Sarah Knowles, Karina Lovell, Elizabeth Littlewood, Richard Mattock, Stephen Palmer, Jodi Pervin, David Richards, Debbie Tallon, David White, Simon Walker, Gillian Worthy, Simon Gilbody
Publikováno v:
Health Technology Assessment, Vol 20, Iss 89 (2016)
Background: Computerised cognitive behaviour therapy (cCBT) is an efficient form of therapy potentially improving access to psychological care. Indirect evidence suggests that the uptake and effectiveness of cCBT can be increased if facilitated by te
Externí odkaz:
https://doaj.org/article/062961529e75492181976b556818f712
Autor:
Gillian Worthy
Publikováno v:
Swiss Medical Weekly, Vol 145, Iss 0506 (2015)
When performing statistical peer review for Swiss Medical Weekly papers there often appear to be common errors or recurring themes regarding the reporting of study designs, statistical analysis methods, results and their interpretation. In order to h
Externí odkaz:
https://doaj.org/article/ce2235b92a2b4ca992e69d23acb51fe9
Autor:
Rob Riemsma, Manuela A. Joore, Xavier Pouwels, Shona H. Lang, Sabine Grimm, Nigel Armstrong, Svenja Petersohn, Lisa Stirk, Gillian Worthy, Bram Ramaekers, Janine Ross, Jos Kleijnen
Publikováno v:
PharmacoEconomics. 37:655-667
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Bristol-Myers Squibb) of nivolumab (Opdivo (R)) to submit evidence of its clinical and cost effectiveness
Autor:
Rob Riemsma, Gillian Worthy, Bram Ramaekers, Willem J.A. Witlox, Debra Fayter, Caro Noake, Nigel Armstrong, Jos Kleijnen, Svenja Petersohn, Xavier Pouwels, Sabine Grimm, Manuela A. Joore
Publikováno v:
Pharmacoeconomics
As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Merck Sharp & Dohme; MSD) of pembrolizumab (Keytruda (R)) to submit evidence of its clinical and cost eff
Autor:
Caro Noake, V. Huertas Carrera, Steve Ryder, Irmgard Boesl, Gillian Worthy, Titas Buksnys, Stephanie L. Swift, Joseph Kleijnen, Hiltrud Liedgens, Nigel Armstrong
Publikováno v:
Value in Health. 22:S708
Autor:
G Worth, Jos Kleijnen, Gillian Worthy, Sarah Bray, Ian Bridges, Naveed Sattar, Shravanthi R. Gandra, Ricardo Dent, Carol A. Forbes, Erik S.G. Stroes, L Cheng, Peter P. Toth, Sohan Deshpande, Janine Ross
Publikováno v:
Journal of the American Heart Association, 6(10):116.005367. Wiley-Blackwell
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The proprotein convertase subtilisin/kexin type 9 ( PCSK 9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol ( LDL ‐C) when added to statin therapy in patients who need additional LDL ‐C r
Autor:
David Kessler, Thomas Devlin, Ricardo Araya, Cindy Cooper, Lucy Smith, Peter Bower, Sarah Knowles, Debbie Tallon, Elizabeth Littlewood, David Richards, Simon Gilbody, Gillian Worthy, Sally Brabyn, Karina Lovell, Michael Barkham, David White, Reeact collaborative
Publikováno v:
Gilbody, S, Brabyn, S, Lovell, K, Kessler, D, Devlin, T, Smith, L, Araya, R, Barkham, M, Bower, P, Cooper, C, Knowles, S, Littlewood, E, Richards, D A, Tallon, D, White, D, Worthy, G 2017, ' Telephone-supported computerised cognitive-behavioural therapy : REEACT-2 large-scale pragmatic randomised controlled trial ', British Journal of Psychiatry, vol. 210, no. 5, pp. 362-367 . https://doi.org/10.1192/bjp.bp.116.192435
BackgroundComputerised cognitive–behavioural therapy (cCBT) for depression has the potential to be efficient therapy but engagement is poor in primary care trials.AimsWe tested the benefits of adding telephone support to cCBT.MethodWe compared tele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f33e3741e59268af1d651d8cfd770b85
https://hdl.handle.net/1983/8870f84e-8ae5-4cb9-9ee5-56b41dab2a9e
https://hdl.handle.net/1983/8870f84e-8ae5-4cb9-9ee5-56b41dab2a9e
Autor:
Ricardo Araya, Ana Duarte, Jodi Pervin, Sarah Knowles, Debbie Tallon, David Richards, Richard Mattock, David White, Stephen Palmer, Elizabeth Littlewood, Michael Barkham, Gillian Worthy, Karina Lovell, Sally Brabyn, Cindy Cooper, Simon Gilbody, Simon Walker, Peter Bower, David Kessler
Publikováno v:
Health Technology Assessment, Vol 20, Iss 89 (2016)
Bower, P 2016, ' The second Randomised Evaluation of the Effectiveness, cost-effectiveness and Acceptability of Computerised Therapy (REEACT-2) trial: does the provision of telephone support enhance the effectiveness of computer-delivered cognitive behaviour therapy? A randomised controlled trial ', Health Technology Assessment, vol. 20, no. 89, pp. 1-63 . https://doi.org/10.3310/hta20890
Brabyn, S, Araya, R, Barkham, M, Bower, P, Cooper, C, Duarte, A, Kessler, D, Knowles, S, Lovell, K, Littlewood, E, Mattock, R, Palmer, S, Pervin, J, Richards, D, Tallon, D, White, D, Walker, S, Worthy, G & Gilbody, S 2016, ' The second Randomised Evaluation of the Effectiveness, cost-effectiveness and Acceptability of Computerised Therapy (REEACT-2) trial : does the provision of telephone support enhance the effectiveness of computer-delivered cognitive behaviour therapy? A randomised controlled trial ', Health Technology Assessment, vol. 20, no. 89, pp. 1-64 . https://doi.org/10.3310/hta20890
Bower, P 2016, ' The second Randomised Evaluation of the Effectiveness, cost-effectiveness and Acceptability of Computerised Therapy (REEACT-2) trial: does the provision of telephone support enhance the effectiveness of computer-delivered cognitive behaviour therapy? A randomised controlled trial ', Health Technology Assessment, vol. 20, no. 89, pp. 1-63 . https://doi.org/10.3310/hta20890
Brabyn, S, Araya, R, Barkham, M, Bower, P, Cooper, C, Duarte, A, Kessler, D, Knowles, S, Lovell, K, Littlewood, E, Mattock, R, Palmer, S, Pervin, J, Richards, D, Tallon, D, White, D, Walker, S, Worthy, G & Gilbody, S 2016, ' The second Randomised Evaluation of the Effectiveness, cost-effectiveness and Acceptability of Computerised Therapy (REEACT-2) trial : does the provision of telephone support enhance the effectiveness of computer-delivered cognitive behaviour therapy? A randomised controlled trial ', Health Technology Assessment, vol. 20, no. 89, pp. 1-64 . https://doi.org/10.3310/hta20890
BackgroundComputerised cognitive behaviour therapy (cCBT) is an efficient form of therapy potentially improving access to psychological care. Indirect evidence suggests that the uptake and effectiveness of cCBT can be increased if facilitated by tele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b50c779f2a620bc549be5177f1936507
Autor:
Joanna Burns, David A.S.G. Mary, John P Greenwood, Stephen G. Ball, Allan D. Struthers, Gillian Worthy
Publikováno v:
Journal of Hypertension. 30:2039-2046
Neuroendocrine activation may be an important adjunctive mechanism for left ventricular hypertrophy (LVH) development. Controversy exists to as to whether LVH regression occurs due to blood pressure (BP) reduction alone or if adjunctive mechanisms pl